Your browser doesn't support javascript.
loading
Monocyte chemoattractant protein-1: a proinflammatory cytokine elevated in sarcopenic obesity.
Lim, Jun Pei; Leung, Bernard P; Ding, Yew Yoong; Tay, Laura; Ismail, Noor Hafizah; Yeo, Audrey; Yew, Suzanne; Chong, Mei Sian.
Afiliação
  • Lim JP; Department of Geriatric Medicine, Tan Tock Seng Hospital, Singapore ; Institute of Geriatrics and Active Ageing, Tan Tock Seng Hospital, Singapore.
  • Leung BP; Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore.
  • Ding YY; Department of Geriatric Medicine, Tan Tock Seng Hospital, Singapore ; Institute of Geriatrics and Active Ageing, Tan Tock Seng Hospital, Singapore.
  • Tay L; Department of Geriatric Medicine, Tan Tock Seng Hospital, Singapore ; Institute of Geriatrics and Active Ageing, Tan Tock Seng Hospital, Singapore.
  • Ismail NH; Institute of Geriatrics and Active Ageing, Tan Tock Seng Hospital, Singapore ; Department of Community and Continuing Care, Tan Tock Seng Hospital, Singapore.
  • Yeo A; Institute of Geriatrics and Active Ageing, Tan Tock Seng Hospital, Singapore.
  • Yew S; Institute of Geriatrics and Active Ageing, Tan Tock Seng Hospital, Singapore.
  • Chong MS; Department of Geriatric Medicine, Tan Tock Seng Hospital, Singapore ; Institute of Geriatrics and Active Ageing, Tan Tock Seng Hospital, Singapore.
Clin Interv Aging ; 10: 605-9, 2015.
Article em En | MEDLINE | ID: mdl-25848236
ABSTRACT

OBJECTIVE:

Sarcopenic obesity (SO) is associated with poorer physical outcomes and functional status in the older adult. A proinflammatory milieu associated with central obesity is postulated to enhance muscle catabolism. We set out to examine associations of the chemokine monocyte chemoattractant protein-1 (MCP-1) in groups of older adults, with sarcopenia, obesity, and the SO phenotypes.

METHODS:

A total of 143 community dwelling, well, older adults were recruited. Cross-sectional clinical data, physical performance, and muscle mass measurements were collected. Obesity and sarcopenia were defined using revised National Cholesterol Education Program (NCEP) obesity guidelines and those of the Asian Working Group for Sarcopenia. Serum levels of MCP-1 were measured by enzyme-linked immunosorbent assay (ELISA).

RESULTS:

In all, 25.2% of subjects were normal, 15.4% sarcopenic, 48.3% obese, and 11.2% were SO. The SO groups had the lowest appendicular lean mass, highest percentage body fat, and lowest performance scores on the Short Physical Performance Battery and grip strength. The MCP-1 levels were significantly different, with the highest levels found in SO participants (P<0.05).

CONCLUSION:

Significantly raised MCP-1 levels in obese and SO subjects support the theory of chronic inflammation due to excess adiposity. Longitudinal studies will reveal whether SO represents a continuum of obesity causing accelerated sarcopenia and cardiovascular events, or the coexistence of two separate conditions with synergistic effects affecting functional performance.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quimiocina CCL2 / Sarcopenia / Obesidade Tipo de estudo: Guideline / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quimiocina CCL2 / Sarcopenia / Obesidade Tipo de estudo: Guideline / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Ano de publicação: 2015 Tipo de documento: Article